Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2020 2
2021 1
2022 1
2023 2
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Keller PJ, Adams EJ, Wu R, Côté A, Arora S, Cantone N, Meyer R, Mertz JA, Gehling V, Cui J, Stuckey JI, Khanna A, Zhao F, Chen Z, Yu Z, Cummings RT, Taimi M, Lakhani NJ, Rasco D, Gutierrez M, Duska L, Devitt M, Rippley R, Levell J, Truong J, Wang J, Sun K, Trojer P. Keller PJ, et al. Cancer Res. 2024 Aug 1;84(15):2501-2517. doi: 10.1158/0008-5472.CAN-24-0398. Cancer Res. 2024. PMID: 38833522 Free PMC article. Clinical Trial.
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.
Ray-Coquard IL, Savoye AM, Schiffler C, Mouret-Reynier MA, Derbel O, Kalbacher E, LeHeurteur M, Martinez A, Cornila C, Martinez M, Bengrine Lefevre L, Priou F, Cloarec N, Venat L, Selle F, Berton D, Collard O, Coquan E, Le Saux O, Treilleux I, Gouerant S, Angelergues A, Joly F, Tredan O. Ray-Coquard IL, et al. Nat Commun. 2024 Jul 16;15(1):5931. doi: 10.1038/s41467-024-46999-x. Nat Commun. 2024. PMID: 39013870 Free PMC article. Clinical Trial.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. Piha-Paul SA, et al. Oncologist. 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338. Oncologist. 2024. PMID: 38297981 Free PMC article. Clinical Trial.
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. Fontana E, et al. J Natl Cancer Inst. 2024 Sep 1;116(9):1439-1449. doi: 10.1093/jnci/djae098. J Natl Cancer Inst. 2024. PMID: 38710487 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, De Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S. Hamilton E, et al. Clin Cancer Res. 2024 Dec 16;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513. Clin Cancer Res. 2024. PMID: 39405343 Free PMC article. Clinical Trial.
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
van der Kleij MBA, Guchelaar NAD, Meertens M, Westerdijk K, Giraud EL, Bleckman RF, Groenland SL, van Eerden RAG, Imholz ALT, Vulink AJE, Otten HM, Fiebrich-Westra HB, Lubberman FJE, Desar IME, Moes DAR, Touw DJ, Koolen SLW, Gelderblom H, Reyners AKL, van Erp NP, Mathijssen RHJ, Huitema ADR; Dutch Pharmacology Oncology Group (DPOG); Steeghs N. van der Kleij MBA, et al. Br J Cancer. 2024 Sep;131(5):843-851. doi: 10.1038/s41416-024-02789-2. Epub 2024 Jul 6. Br J Cancer. 2024. PMID: 38971952 Free PMC article.
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.
Kabirian R, Tredan O, Marmé F, Paoletti X, Eberst L, Lebreton C, De La Motte Rouge T, Sabatier R, Angelergues A, Fabbro M, Van Gorp T, Mansi L, Gladieff L, Kaczmarek E, Alexandre J, Grellety T, Favier L, Welz J, Frenel JS, Leary A. Kabirian R, et al. Future Oncol. 2024;20(35):2699-2708. doi: 10.1080/14796694.2024.2386922. Epub 2024 Aug 19. Future Oncol. 2024. PMID: 39155847 Free PMC article.
18 results